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ABSTRACT 
 
Aspects on Diagnosis and Treatment of Gastrointestinal Neuroendocrine 
Tumours 
Background. Gastroenteropancreatic neuroendocrine tumours (GEP-NETs) originate from 
endocrine cells of the intestinal mucosa and pancreas. The tumour cells contain chromogranin A 
(CgA) and usually have a high expression of somatostatin receptors (SSTR), which can be used 
for diagnosis and treatment. The treatment alternatives in patients with disseminated GEP-NETs 
include debulking surgery, hepatic arterial embolization (HAE), in selected cases orthotopic liver 
transplantation (OLT), or somatostatin receptor (SSTR)-mediated radiation therapy besides 
medical treatment with somatostatin analogues, interferon, or combination of cytotoxic drugs.  
 
Material & Methods. A xenograft model with a transplantable midgut carcinoid tumour (GOT 
1) was used to study the correlation between tumour weight and the tumour marker chromogranin 
A (CgA) in plasma as well as the therapeutic effects of the somatostatin analogue octreotide. The 
uptake and biodistribution of the radiopharmaceuticals 177Lu-octreotide and 177Lu-octreotate in 
GOT 1-bearing nude mice were studied. A consecutive series of 107 patients treated with HAE 
was analyzed regarding biochemical response and survival. The effect of SSTR-mediated 
radiation therapy was analyzed in a consecutive series of 26 patients with disseminated GEP-
NETs as well as in 6 patients with non-resectable recurrence of tumour after OLT. The absorbed 
dose to the kidney as a tool for optimization of radiotherapy was evaluated.  
 
Results. In GOT 1-bearing nude mice there was a strong correlation between tumour weight and 
P-CgA (P<0.00001). The P-CgA/tumour weight ratio was significantly lowered by octreotide 
(P<0.037). The uptake of 177Lu-octreotate was twice that of 177Lu-octreotide (P=0.00061) and the 
reduction of tumour volume was significantly higher in animals given 177Lu-octreotate 
(P=0.003). The tumour volume correlated significantly with P-CgA, which served as a marker of 
treatment effect. A good biochemical response with decreased tumour markers correlated with 
prolonged survival in patients after HAE (P=0.003). There was also a significant correlation 
between the responses to primary and repeat HAE. SSTR-mediated radiation therapy resulted in 
38% partial tumour reduction according to RECIST-criteria. By using the absorbed dose to the 
kidney as a limiting factor for therapy we found that 10 patients received fewer than 4 treatments 
but 4 patients were identified as candidates for additional treatment. There was a significant 
reduction of glomerular filtration rate (GFR) after radiotherapy (P=0.0013). Also in transplanted 
patients SSTR-mediated radiation therapy could be used to treat tumour recurrence.  
 
Conclusions. 1. P-CgA was well suited for monitoring of the tumour burden and tumour 
response in GOT 1-bearing nude mice. 2. 177Lu-octreotate was a more suitable 
radiopharmaceutical than 177Lu-octreotide and the in vivo data allowed accurate determination of 
absorbed dose. 3. HAE provided prolonged survival in biochemically responsive patients. Repeat 
HAE can be considered in patients with favourable response to the first procedure. 4. Calculation 
of the accumulated dose to the kidneys during SSTR-mediated radiotherapy was valuable to 
optimize the treatment. 5. SSTR-mediated radiotherapy was a treatment option also for patients 
with non-resectable recurrence of SSTR-expressing tumours, previously treated with OLT.  
 
Key words: Carcinoid, endocrine pancreatic tumour, neuroendocrine, octreotide, somatostatin 
receptor, peptide receptor radionuclide therapy, absorbed dose, chromogranin A, liver 
transplantation.  
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ABBREVIATIONS 
 
b.w.   Body weight 
CgA   Chromogranin A 
CI   Confidence interval 
CR   Complete response 
CT   Computed tomography 
CTC   Common toxicity criteria 
EC cell   Enterochromaffin cell 
ECL cell   Enterochromaffin-like cell 
EPT   Endocrine pancreatic tumour 
FISH   Fluorescence in situ hybridization 
GEP-NET   Gastroenteropancreatic neuroendocrine tumour 
GI   Gastrointestinal 
HAE   Hepatic artery embolization 
5-FU   5-fluorouracil 
5-HIAA   5-hydroxyindole acetic acid 
5-HT   5-hydroxytryptamine, serotonin 
HR   Hazard ratio 
IFN-α   Interferon α 
i.v.   Intravenous 
mTOR   Mammalian target of rapamycin 
MVT   Multivisceral transplantation 
NAD+   Nicotine amide adenine dinucleotide 
NE   Neuroendocrine 
OLT   Orthotopic liver transplantation 
PARP1   Poly (ADP-ribose) polymerase 1 
P-CgA   Plasma chromogranin A  
PD   Progressive disease 
PDEC   Poorly differentiated endocrine carcinoma 
PR   Partial response 
PRRT   Peptide receptor-radionuclide therapy 
RECIST   Response evaluation criteria in solid tumours 
s.c.   Subcutaneous 
SD   Stable disease 
SEM   Standard error of the mean 
SIR   Selective internal radiotherapy 
SPECT   Single photon emission computed tomography 
SSTR   Somatostatin receptor 
STZ   Streptozotocin 
TKI   Tyrosine kinase inhibitor 
tU-5-HIAA  Total urinary 5-hydroxyindole acetic acid 
VEGF   Vascular endothelial growth factor 
WDEC   Well-differentiated endocrine carcinoma 
WDET   Well-differentiated endocrine tumour 
VMAT   Vesicular monoamine transporter 
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INTRODUCTION 
 
Pathology and clinical features of neuroendocrine tumours 
Gastroenteropancreatic neuroendocrine tumours (GEP-NETs) originate from 
endocrine cells of the gastrointestinal mucosa and pancreas. There are at least 14 
specialized cell types in the diffuse endocrine system of the gut. They are all part of 
a complex regulatory network, each cell type synthesizing and secreting specific 
peptide hormones and biogenic amines. The endocrine cells are characterized by 
neurosecretory granules containing both amines and peptide hormones. Examples 
of different subtypes of endocrine cells and their main secretory products are; A-
cells/glucagon and B-cells/insulin in the pancreas, D-cells/somatostatin in the 
pancreas and intestine, EC-like (ECL) cells/ histamine and G-cells/gastrin in the 
stomach, enterochromaffin (EC) cells/serotonin (5-HT) and tachykinins in the 
intestine (Rindi et al., 2004). 
The most common neuroendocrine (NE) tumours of the gastrointestinal (GI) tract 
are the carcinoid tumours followed by endocrine pancreatic tumours (EPT), with an 
incidence in clinical series of 2,5/100.000 and 1/100.000, respectively (Crocetti et 
al., 1997; Hemminki & Li, 2001; Lepage et al., 2004; Levi et al., 2000; Modlin et 
al., 2003; Newton et al., 1994; Quaedvlieg et al., 2001; Westergaard et al., 1995). 
In a large Swedish autopsy study the annual incidence of GI carcinoids was 8.4 per 
100.000 inhabitants (Berge & Linell, 1976). Many carcinoids are small and 
asymptomatic, which is one explanation for the higher incidence in autopsy series.  
Carcinoid tumours were initially classified into three groups, based on their 
embryological origin, i.e. foregut (thymus, lung, oesofagus, stomach and 
duodenum), midgut (jejunum, ileum, appendix) and hindgut (colon and rectum) 
tumours (Williams & Sandler, 1963). This classification has been replaced by the 
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WHO classification (Solcia et al., 2000) dividing NE tumours according to their 
degree of differentiation; well-differentiated endocrine tumours (benign or 
uncertain behaviour, WDET), well-differentiated endocrine carcinomas (low-grade 
malignant behaviour, WDEC), and poorly differentiated endocrine carcinomas 
(high-grade malignant carcinomas, PDEC). A TNM classification and grading 
system has been added by the European Neuroendocrine Tumour Society (ENETS) 
(Rindi et al., 2006). 
GEP-NETs are rare, but still constitute the most common malignancy of the small 
bowel (Godwin, 1975; Modlin et al., 2003). Characteristic for these tumours is their 
hormonal secretory properties, causing clinical symptoms related to hormone 
overproduction. Carcinoid tumours in the small bowel (midgut) are composed of 
EC cells. Secretion of serotonin (5-HT) and tachykinins give rise to the midgut 
carcinoid syndrome characterized by facial flush, diarrhea (each 80%), right-sided 
cardiac valvular lesions (20-40%), and bronchoconstriction (10%, carcinoid 
asthma) (Grahame-Smith, 1972). The gastric carcinoid tumours arise from ECL 
cells of the corpus region and can result in a clinical syndrome characterized by 
lacrimation, bronchial obstruction, generalized flush, and oedema due to histamine 
release (the atypical carcinoid syndrome). The colorectal carcinoid tumours, 
originating from EC-, L- and P-cells, rarely result in a hormonal syndrome. 
Endocrine pancreatic tumours can be classified on clinical grounds as functioning, 
or non-functioning, depending on whether they are hormone-producing, or not 
(Jensen, 1999). Each specific cell type in pancreatic islets can give rise to a 
characteristic tumour and hormonal syndrome, e.g. A-cells give rise to 
glucagonomas, B-cells to insulinomas, and D-cells to somatostatinomas. 
Histopathologically, EPTs are also classified as WDET, WDEC and PDEC.  
The prognosis of GEP-NETs is related to the grade and site of the primary and to 
the extent of disease at diagnosis (Godwin, 1975; Greenberg et al., 1987; 
McDermott et al., 1994; Rindi et al., 2007). Non-metastatic tumours with the 
primary site in the small intestine, or colon, have significantly worse prognosis than 
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those occurring in the lung, stomach, appendix or rectum (Modlin et al., 2003). 
WDEC have a relatively slow growth rate and are usually first clinically diagnosed 
with locoregional and distant spread. PDEC of the GI tract have sinister prognosis 
and are only rarely surgically curable, but temporary tumour responses can be 
achieved by chemotherapy (cisplatin and etoposide) (Brenner et al., 2004; Brenner 
et al., 2007).  
 
Biochemical markers of neuroendocrine tumours 
Chromogranin A 
Chromogranin A (CgA) is a 75 kDa glycoprotein that was first isolated from 
chromaffin granules of bovine adrenal medulla (Smith & Winkler, 1967), and was 
found to be co-secreted with catecholamines. CgA is produced exclusively by 
endocrine and NE cells (Deftos, 1991). It is co-localized with amines and peptides 
in the dense core secretory granules. The function of CgA is not fully elucidated, 
but it plays a role in targeting peptide hormones and neurotransmitters to granules. 
It also serves as a precursor for several biologically active peptides such as 
vasostatin, ß-granin, chromostatin, pancreastatin and parastatin. These peptides act 
predominantly as inhibitors of hormone and neurotransmittor release in an 
autocrine and paracrine fashion (Deftos, 1991; Helle et al., 2007; Hendy et al., 
1995). The almost universal presence of CgA in NE cells provides a tool for 
immunohistochemical identification of NE tumours regardless of their hormonal 
activity, location, and degree of differentiation. For histopathological purposes, 
other NE markers are available, i.e. synaptic vesicle protein 2, neuron-specific 
enolase and synaptophysin (Jakobsen et al., 2002; Portela-Gomes et al., 1999; 
Vyberg et al., 1990). Since CgA is secreted into the circulation, it can also be used 
as a tumour marker in plasma (Stridsberg et al., 1995). P-CgA seems to be the most 
reliable marker for NE tumours, both in terms of specificity (86%) and sensitivity 
(68%) (Bajetta et al., 1999; Baudin et al., 1998).  
   12 
5-Hydroxyindole acetic acid  
The main secretory product of EC cells and ileal carcinoids is serotonin, 5-
hydroxytryptamin (5-HT). After dehydrogenation and degradation of 5-HT by 
monoamine oxidase in the in liver and lung, 5-hydroxyindole acetic acid (5-HIAA) 
is excreted in the urine (Gillies, 1979; Grahame-Smith, 1972). The rapid turnover 
and the large 5-HT pool in platelets make measurements of 5-HT in serum less 
reliable for clinical use. Urinary 5-HIAA (24 hrs) is still one of the most frequently 
used diagnostic tools for midgut carcinoids. 5-HIAA levels have a high specificity 
(100%) but low sensitivity (35.1%) (Bajetta et al., 1999) in the detection of midgut 
carcinoid tumours; 5-HIAA is most valuable in patients with metastatic disease, in 
whom it serves as a tumour marker to follow the course of the disease and the 
effect of therapy.  
 The carcinoid valvular heart disease (usually tricuspid insufficiency sometimes 
combined with pulmonary stenosis) is believed to be caused by fibroblast-
stimulating factors, i.e. 5-HT and tachykinins, secreted from liver metastases, or to 
local factors from the peritoneal cavity, e.g. transforming growth factor β1 and 
connective tissue growth factor (Kidd et al., 2007; Modlin et al., 2009) . The 
presence of heart disease has been shown to correlate with high 5-HT turnover, 
manifested by high tU-5-HIAA (Bernheim et al., 2007; Himelman & Schiller, 
1989; Pellikka et al., 1993; Westberg et al., 2001).  
 
Somatostatin receptors   
Somatostatin receptors (SSTR) are widely distributed in the body. They are 
involved in regulation of gut motility, fluid secretion, hormone release and growth. 
A variety of tumour types express SSTR, especially NE tumours which may over-
express SSTR 100-fold compared to normal tissue resulting in high tumour-to-
blood uptake ratios after administration of radiolabeled somatostatin analogue 
(Forssell-Aronsson et al., 2004; Forssell-Aronsson et al., 1995). There are 5 
characterized subtypes of SSTR, SSTR1-5. They are all G-protein-coupled 
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receptors with 7 transmembrane domains. Using Northern blot, or real time 
quantitative PCR, the SSTR profile of individual tumours can be determined. 
Midgut carcinoid tumours express all subtypes, but with dominance of SSTR2&5 
(Kölby et al., 1998). Native somatostatin has high affinity for all 5 subtypes, while 
the somatostatin analogue octreotide has high affinity only for SSTR2&5 (Susini & 
Buscail, 2006). The presence of SSTR on NE tumour cells provides a tool both for 
tumour visualization with scintigraphic techniques and peptide receptor 
radionuclide therapy (PRRT).  
 
Treatment modalities  
Surgical treatment 
The only curative treatment for GEP-NETs is radical surgery at the time of 
localized disease. In the few patients who are diagnosed at an early stage, curative 
surgery should be attempted, including resection of the primary tumour, regional 
lymph node metastases and liver resection if limited hepatic spread is present. This 
can lead to total remission for prolonged periods (Wängberg et al., 1996). 
However, the tumour is often diagnosed first when the disease is widely 
disseminated. Patients with bilobar hepatic metastases should still undergo surgery 
aiming at reduction of extrahepatic tumour so that continued treatment can be 
focused on the hepatic tumour disease. Cholecystectomy is included in the surgical 
procedure to prevent somatostatin analogue-induced gall stones, and to avoid gall 
bladder gangrene during HAE (Simons et al., 1992; Takayasu et al., 1985). The 
slow progression of these tumours makes active tumour reduction highly 
motivated. Resection of lymph node metastases along the superior mesenteric 
artery (a common feature in ileal carcinoids) together with excision of mesenterial 
fibrosis, can be helpful to re-establish the circulation of the small bowel.  
In the first report from our group (Wängberg et al., 1996), 64 patients with 
disseminated midgut carcinoids and hepatic metastases were treated according to a 
uniform clinical protocol aiming at aggressive tumour reduction by surgery alone, 
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or in combination with hepatic artery embolization (HAE). Fourteen patients (22%) 
reached remission by surgery alone, forty patients (63%) with bilobar liver 
metastases underwent HAE in combination with octreotide treatment. Ten patients 
(15%) with bilobar liver metastases were not embolized because of complicating 
diseases. The 5-year survival for the entire series was 58%, which compared most 
favourably with other patient series at that time; only 19-21% in the early series 
(Godwin, 1975; Moertel et al., 1961) and 38% in a simultaneous report (Jacobsen 
et al., 1995). In later series the 5-year survival of patients with liver metastases 
varied between 47-53% including data from single centres and large tertiary 
referral centres (Chamberlain et al., 2000; Nave et al., 2001; Sarmiento & Que, 
2003; Sutcliffe et al., 2004). 
 
Somatostatin analogue treatment  
Somatostatin was first isolated from the hypothalamus (Krulich et al., 1968) and 
later found to be localized also in the D-cells of the GI tract (Reichlin, 1983a; 
Reichlin, 1983b; Shulkes, 1994). Somatostatin reduces smooth muscle contractility 
and glandular secretion by inhibiting cAMP. Physiologically somatostatin regulates 
hormone secretion from the anterior pituitary, pancreas and GI tract. Native 
somatostatin reduced symptoms in patients with GEP-NETs, but short half-life 
made its clinical use limited. In 1984, the first somatostatin analogue, octreotide, 
was tested in a phase II study. With a half-life of 90 minutes, octreotide can be 
administered every 6-12 hours. Octreotide has high affinity for SSTR2&5 (Bruns et 
al., 1994) and have direct inhibitory effects on the tumour cells, reducing the 
synthesis and release of 5-HT (Wängberg et al., 1991). With the introduction of 
somatostatin analogues, hormonal symptoms could be effectively treated and 
patients with the midgut carcinoid syndrome could undergo surgery without crisis 
reactions and unstable blood pressure (Ahlman et al., 1988; Ahlman et al., 1987; 
Eriksson & Öberg, 1999).   
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Common transient adverse effects during the first weeks of treatment with 
somatostatin analogues include abdominal discomfort, bloating and steatorrhea. 
Cholestasis with formation of cholecystolithiasis occur in up to 60% of the patients, 
due to inhibition of cholecystokinin and production of lithogenic bile (Redfern & 
Fortuner, 1995), which further supports prophylactic cholecystectomy at time for 
primary surgery in GEP-NET-patients.  
In vitro high doses of somatostatin analogues induce apoptosis in tumour cells 
leading to retarded growth. There are several clinical reports suggesting a tumour-
stabilizing effect of somatostatin analogues (Arnold et al., 1996; Shojamanesh et 
al., 2002; Susini & Buscail, 2006; Verslype et al., 2009). In a recent randomized 
prospective study, long-lasting octreotide (LAR) prolonged the time to tumour 
progression from 6 to14 months in patients with midgut carcinoids (Rinke et al., 
2009). 
 
Peptide receptor radionuclide therapy 
The high expression of SSTR in NE tumours can be used for diagnostic and 
therapeutic purposes, since the receptor complex is internalized by the tumour cells 
after ligand binding (Andersson et al., 1996). Coupling of chelators may change the 
affinity of octreotide to SSTR. Using DOTA as a chelator decreases the SSTR2-
affinity for octreotide 7-fold, while the somatostatin analogue octreotate retains 
very high SSTR2-affinity when chelated with DOTA (Reubi et al., 2000). The most 
common radiopharmaceutical for diagnostic procedures has been [111In-DTPA0]-
octreotide; 111In emits primarily Auger electrons and photons. Treatment with 
[111In-DTPA0]-octreotide resulted in reduction of biochemical markers, but 
objective tumour regression was unusual (Fjälling et al., 1996; Krenning et al., 
1999; Tiensuu Janson et al., 1999; Valkema et al., 2002). Other radionuclides (beta-
emitters) were combined with new somatostatin analogues and chelators, which 
resulted in improved radiopharmaceuticals with enhanced binding to specific SSTR 
and more suitable radiation types emitted by the radionuclide aimed for therapy 
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(Bernhardt et al., 2001). The use of [90Y-DOTA, Tyr3]-octreotide resulted in partial 
tumour regression in up to 24% of the first patients treated (Paganelli et al., 2001; 
Waldherr et al., 2001). Today the most frequently used radiopharmaceutical is 
[177Lu-DOTA0, Tyr3]-octreotate. 177Lu has a half-life of 6.7 days, and emits both 
beta- and gamma radiation, which allows imaging and dosimetry at the time of 
radiotherapy. [177Lu-DOTA0, Tyr3]-octreotate has longer tumour residence time (by 
a factor of 2.1) than [177Lu-DOTA0, Tyr3]-octreotide (Esser et al., 2006). This 
probably relates to higher affinity to SSTR2, which is the main SSTR subtype 
expressed by midgut carcinoids (Kwekkeboom et al., 2001; Kölby et al., 1998; 
Reubi et al., 2000). 
[177Lu-DOTA0, Tyr3]-octreotate treatment of patients with disseminated GEP-NETs  
resulted in 46% objective tumour responses (very few complete remissions and a 
majority of partial or minor tumour regressions) in a large series of 310 patients 
(Kwekkeboom et al., 2008). The dose-limiting factors are kidney and bone marrow 
toxicity. Careful dosimetry is essential to reach as high absorbed dose to the tumour 
tissue as possible without causing severe adverse effects, i.e. renal or bone marrow 
failure. Kidney doses can be calculated from planar scintigraphic images, or from 
single photon emission computed tomography (SPECT) images. Absorbed dose to 
the bone marrow is more difficult to assess, since it requires measurements of 
biopsy material.  
PRRT-studies have so far reported that the procedure is well tolerated with few 
severe adverse effects. The tumour response rate is relatively high and the 
progression-free survival of patients is probably prolonged. The survival benefit 
has not yet been studied in randomized series. The most important factors for 
predicting objective tumour responses seem to be high radionuclide uptake on 
octreotide scintigraphy and a good performance status of the patient (Kwekkeboom 
et al., 2008). 
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Hepatic artery embolization 
Interventions involving the hepatic artery for therapeutic purposes were first 
proposed by Markowitz in 1952 and various techniques have been employed to 
induce tumour ischaemia, initially hepatic artery ligation (Markowitz, 1952; 
Nilsson, 1966). This procedure rarely achieved adequate ischaemia due to a rich 
collateral blood supply. The interventions could not be repeated and the technique 
was associated with high mortality in the pre-somatostatin analogue era. The 
method most frequently used today is selective HAE. The hepatic artery is first 
catheterized followed by injection of the embolization material in peripheral 
branches related to vascular anatomy and tumour localization. This procedure 
causes a relatively selective ischaemia of the tumour metastases, since the normal 
liver parenchyma has a dual blood supply from the hepatic artery and the portal 
vein (Cho et al., 1976). Patency of the portal vein is therefore a prerequisite for 
HAE to be performed. HAE is a well established palliative treatment for bilobar 
liver metastases from NE tumours and has been shown to give good control of 
hormonal symptoms. It is effective in reducing hormone levels and symptoms in 
patients with objective radiological tumour regression in response to the procedure; 
a biochemical effect that can last for several years (Wängberg et al., 1996). In 
addition, a survival advantage after HAE has been suggested in previous studies 
(Gupta et al., 2005; Gupta et al., 2003; Jacobsen et al., 1995; Mitty et al., 1985). 
HAE can be combined with intra-arterial injection of chemotherapeutic agents 
(HACE, or chemoembolization) to the liver. Combining HACE with octreotide 
treatment in patients with advanced hepatic carcinoid metastases resulted in 
shrinkage of the tumours in 85% of the patients; the mean reduction of tumour 
markers was 50-75%. The procedure was well-tolerated and without severe adverse 
effects (Drougas et al., 1998). 
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Radiofrequency ablation 
Solitary liver metastases of moderate size (< 3 cm) can be successfully treated with 
ultrasound-guided percutaneous radiofrequency ablation (Elvin et al., 2005; 
Hellman et al., 2002). The method can also be applied during surgery (Berber et al., 
2002). The method is limited not only by tumour size and number, but also by the 
location within the liver and the relation to adjacent vessels, e.g. the portal vein. 
 
Radioembolization 
Radioembolization with 90Y microspheres has been used to treat patients with non-
resectable liver metastases and primary liver carcinoma since more than a decade 
with some success (Carr, 2004; Gray et al., 2001; Stubbs et al., 2001). The 
treatment is performed by injecting 90Y-labeled resin microspheres via the hepatic 
artery. Usually two thirds of the total dose is injected into the right hepatic lobe and 
one third into the left lobe (selective internal radiotherapy, SIR). Patients with liver 
metastases from NE tumours have recently been treated with objective tumour 
responses and few side-effects (Kalinowski et al., 2009; Kennedy et al., 2008; King 
et al., 2008; Rhee et al., 2008). 
 
Chemotherapy  
Chemotherapy can provide palliation for patients with disseminated GEP-NETs. 
The response rate to monotherapy is low, so combinations of chemotherapeutic 
agents are used (e.g. streptozotocin (STZ), fluorouracil (5-FU) and doxorubicin, or 
dacarbazine, etoposide and cisplatin). In one recent trial, patients with EPT were 
treated with STZ, 5-FU and doxorubicin (Kouvaraki et al., 2004) with a response 
rate of 39% and a median progression-free survival of 9.3 months in line with the 
early series (Moertel et al., 1994; Rivera & Ajani, 1998). 
 In patients with GI carcinoid tumours, chemotherapy seems to be less effective 
than in patients with EPT. A recent overview of 10 trials over 25 years (1979-2005) 
indicated a low median response rate of 25% and a median survival of 11 months 
     
 
19 
(Plöckinger, 2008). Etoposide and cisplatin are not effective in patients with 
WDEC tumours, but result in temporary tumour response in two thirds of the 
patients with PDEC tumours (Arnold et al., 2005; Brenner et al., 2004; Brenner et 
al., 2007). 
 
Interferon-α  
The cytokine interferon- α (IFN- α) has been shown to have anti-tumour effects 
mediated via several mechanisms. IFN-α became available for treatment of patients 
with the midgut carcinoid syndrome in the 1980s. The dose must be individually 
adjusted using haematological parameters such as leucocyte count. The adverse 
effects of IFN- α may include initial flu-like symptoms, but autoimmune reactions 
occur in 20% of patients (Öberg, 1994). 
Objective tumour reduction was observed in 10% of the patients, but stable disease 
in up to 70% (Dirix et al., 1996; Doberauer et al., 1991; Jacobsen et al., 1995; 
Janson et al., 1992; Moertel et al., 1989; Schober et al., 1992; Smith et al., 1987; 
Öberg & Eriksson, 1989; Öberg & Eriksson, 1991). However, in a national 
prospective randomized clinical trial of patients with midgut carcinoid tumours 
metastatic to the liver, who had previously undergone primary surgical treatment 
and HAE, no survival benefit of IFN-α was shown in addition to the use of a 
somatostatin analogue (Kölby et al., 2003). 
 
Liver transplantation  
Orthotopic liver (OLT), or multivisceral, transplantation (MVT), can be used for 
treatment of metastatic NE tumours, since metastases can be limited to the liver for 
long periods. It may offer control of hormonal symptoms, sometimes even cure, for 
selected patients with favourable biological features (WDEC tumours with limited 
proliferative activity). Resection of the primary tumour (intestinal or pancreatic 
body/tail resection) together with regional lymph nodes, should be performed prior 
to OLT. With an EPT located in the head of the pancreas, MVT may be a treatment 
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alternative. The experience of OLT/MVT is hitherto limited, but in a Gothenburg 
study on 15 patients over 8 years, good relief of hormonal symptoms, long disease-
free survival and potential cure in individual patients were reported (Olausson et 
al., 2007). 
 
Treatment algorithm  
GEP-NETs can be managed by a multitude of treatment modalities. The mainstay 
in treatment of GEP-NETs is surgery and somatostatin analogues. For patients with 
localized disease surgery can lead to total remission. Primary surgery includes 
resection of the primary, lymph node metastases, sometimes liver resection and 
prophylactic cholecystectomy (in preparation for later HAE). As a majority of 
patients are diagnosed at an advanced tumour stage, only a minority can undergo 
curative surgery. Removal of the primary tumour and reduction of the metastases is 
still recommended to reduce local symptoms and hormonal effects. Somatostatin 
analogues alleviate hormonal symptoms and may also have a tumour-stabilizing 
effect (Rinke et al., 2009; Shojamanesh et al., 2002; Susini & Buscail, 2006; 
Verslype et al., 2009). Interferon can offer similar therapeutic effects as 
somatostatin analogues to certain patients (Öberg, 2000; Öberg, 2003). Bilobar 
hepatic metastases can be treated by applied ischemia (HAE), which leads to 
reduced hormone production and often tumour shrinkage. Liver transplantation can 
be a treatment option for selected patients with disease limited to the liver; the 
indications for transplantation have not yet been settled, e.g. the upper limit for the 
proliferative activity of the tumour (Ki67) today varies between 2.35-10% 
(Olausson et al., 2007). Progressive disease after attempts with medical and 
interventional therapy, may be treated systemically by PRRT or chemotherapy 
(Fig. 1). 
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Fig 1. Treatment algorithm. Flow chart representing the treatment algorithm for 
GEP-NETs employed at our unit. Bold arrows indicate our most common treatment 
pathways. 
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RECIST 
Response evaluation of anticancer treatment has not been uniform, which have 
made comparisons between studies difficult. Several organizations involved in 
clinical cancer research first met in 1994, which led to the definition of RECIST 
criteria (Response Evaluation Criteria in Solid Tumours) (Therasse et al., 2000). 
This consensus states that measurements of tumour lesions should be undertaken on 
CT or MRI images. The longest diameter of measurable (>10 mm on spiral CT or 
MRI, >20 mm on conventional CT) lesions up to a maximum of five per organ (a 
maximal total of 10) are measured in the axial plane, giving a sum of diameters at 
baseline. The measured lesions are designated target lesions. Lesions smaller than 
10, or 20 mm, respectively, are considered non-measurable. Examples of non-
measurable lesions are bone lesions, leptomeningeal disease, ascites, 
pleural/pericardial effusion, inflammatory breast disease, lymphangitis in skin and 
lungs, abdominal and cystic lesions. At follow-up the target lesions are re-evaluated 
with the same examination modality as at baseline. The criteria for response are: 
Complete response (CR) – disappearance of all target lesions. 
Partial response (PR) – at least a 30% decrease of the sum of the longest diameter 
of target lesions, taking as reference the baseline sum of longest diameter. 
Progressive disease (PD) – at least a 20% increase of the sum of the longest 
diameter of target lesions, taking as reference the smallest sum of longest diameter, 
recorded since the treatment started, or at the appearance of new lesions. 
Stable disease (SD) – neither sufficient shrinkage to qualify for partial response, 
nor sufficient increase to qualify for progressive disease. 
 
Tumour models 
Few model systems are available for experimental studies of NE tumours. The 
BON cell line was derived from an endocrine pancreatic carcinoid (Evers et al., 
1991), whereas KRJ-I, GOT 1 and CNDT2 cell lines were derived from ileal 
carcinoid tumours (Kölby et al., 2001; Pfragner et al., 1996; Van Buren et al., 
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2007). Primary cell cultures reflect the tumour biology of individual patients most 
accurately but are hampered by the limited availability of material. Studies of 
receptor mechanisms and secretory mechanisms have been performed in cell lines, 
BON being the most widely used. However, BON cells have been shown to have a 
mixed endocrine/exocrine phenotype. The GOT 1 model consists of a 
transplantable midgut carcinoid (EC cell type) derived from a liver metastasis of a 
human ileal carcinoid. Analysis of GOT 1 during several generations, have shown 
that the NE phenotype is well preserved, including expression of SSTR and 
vesicular monoamine transporters (VMAT1&2) (Kölby et al., 2001). This animal 
model with a human midgut carcinoid tumour transplanted s.c. to the back of the 
neck of nude mice, has been most useful for studies of SSTR-expression, secretory 
mechanisms, tumour markers and SSTR-targeted radiotherapy (Bernhardt et al., 
2001; Bernhardt et al., 2003; Bernhardt et al., 2007; Kölby et al., 2005).  
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AIMS 
 
 
1. To evaluate P-CgA as a tumour marker for NE tumours by studying the 
relationship between P-CgA and tumour burden in a xenograft model of 
a human midgut carcinoid (GOT 1) and to analyze the effect on P-CgA 
after medical treatment with a long-acting somatostatin analogue. 
 
2. To evaluate the uptake and therapeutic effect of [177Lu-DOTA0, Tyr3]-
octreotide and [177Lu-DOTA0, Tyr3]-octreotate in the GOT 1 model and 
to evaluate P-CgA as a marker of tumour response. 
 
3. To study the effect of HAE in patients with metastatic ileal carcinoids 
by evaluating biochemical response and survival in a large consecutive 
series of patients treated with HAE. 
 
4. To evaluate radiological and biochemical response to PRRT in patients 
with disseminated NE tumours and to analyze the clinical value of 
monitoring accumulated renal doses for optimization of such treatment. 
 
5. To evaluate possible indications for PRRT and the clinical outcome 
after PRRT in a pilot series of patients with non-resectable recurrence of 
NE tumours, previously subjected to OLT.  
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MATERIAL AND METHODS 
 
Experimental studies (I-II) 
Tumour model 
The xenograft model was established in our laboratory by injecting the human midgut carcinoid 
tumour cell line GOT 1 s.c. in the back of the neck of BALB7cABom-nude mice. This tumour 
has then been successfully propagated through several generations by transplanting small pieces 
of tumour tissue (Kölby et al., 2001). The phenotype has been preserved with identical expression 
of NE markers such as SSTR1-5 and VMAT1&2, as the original tumour. The human origin of 
the transplanted tumour was confirmed by cytogenetic and fluorescence in situ hybridization 
analyses (FISH) (Sjögren et al., 2000). When the tumours had grown to suitable size (2-20 mm in 
diameter), the animals were included in our studies I-II. Measurement of tumour volume was 
performed by measuring two perpendicular diameters with callipers. The volume was calculated 
by the formula 4/3 x πab2, in which a is the longitudinal radius, b is the transverse radius 
(perpendicular radius). 
 
Determination of CgA 
Blood was collected from the animals at sacrifice in heparinized syringes (40 µl heparin 5000 
IE/ml + 1 ml blood). The samples were centrifuged for 20 min at 5000 x g and the plasma aliquot 
frozen at -70°C until assay. P-CgA was determined by using a competitive radioimmunoassay. 
Polyclonal antisera were raised against fragments of CgA, isolated from a patient with midgut 
carcinoid tumour. These fragments had molecular weights of about 30 kDa, covering the amino 
acid sequence 116-439 of human CgA. The CgA preparations were also used for standard and 
tracer preparations. The results were calculated with a logit-log transformation program 
(Pharmacia-LKB). The detection limit was <3 fmol/tube and the total coefficient of variation for 
the assay was <6.4%. No cross-reactions with other chromogranins, or fragments, were observed 
(Stridsberg et al., 1993; Stridsberg et al., 1995). 
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Immunohistochemistry 
Tumour tissues from nude mice were characterized by immunohistochemistry (I). After formalin 
fixation and paraffin embedding the sections were incubated with primary monoclonal antibodies 
against CgA (Boehringer Mannheim, Germany). Bound antibodies were visualized by the 
indirect immunoperoxidase technique (Envision Plus, Dako, Denmark). 
 
Drugs 
The animals (I) were either given long-acting octreotide (Sandostatin-LAR) in low dose (0.286 
mg/kg b.w.) or high dose (2.86 mg/kg b.w.). 
In study II, kits of [DOTA0, Tyr3]-octreotate and [DOTA0, Tyr3]-octreotide were made by mixing 
2.02 mg [DOTA0, Tyr3]-octreotate and 2.02 mg [DOTA0, Tyr3]-octreotide (synthesized by Jörg 
Schmitt, Division of Radiological Chemistry, University Hospital, Basel, Switzerland) with 630 
mg of sodium ascorbate, 125 mg of gentisic acid and 5 mL 0.05 M HCl, respectively. 177LuCl3 
(Perkin Elmer, Life Sciences, Inc., Boston, MA, USA) was diluted in 0.05 M of HCl and mixed 
with [DOTA0, Tyr3]-octreotate or [DOTA0, Tyr3]-octreotide to a specific activity of 30 MBq/µg, 
respectively. The peptide-bound fraction of 177Lu was assessed by instant thin layer 
chromatography with 0.1 M of sodium citrate (pH 5.0) as the mobile phase. The fraction of 
peptide-bound 177Lu was more than 99%. The exact amount of radiopharmaceutical administered 
was determined by measuring the activity in the syringes before and after administration, using a 
well-type ionization chamber. Two groups of tumour-bearing animals were established and 
injected with 15 MBq [177Lu-DOTA0, Tyr3]-octreotide (177Lu-octreotide), or 15 MBq [177Lu-
DOTA0, Tyr3]-octreotate (177Lu-octreotate), respectively. 
 
Determination of absorbed dose to tumours 
The absorbed dose to tumours was calculated (II). The cumulated activity concentration, i.e. the 
total number of radioactive decays per mass unit, was determined by estimating the area under 
the curve for the tumour activity concentration vs time. The electron energy emitted per decay 
was assumed to be 147 keV and absorbed within the tumour as previously described (Bernhardt 
et al., 2001). The contribution of photons was neglected. Also, the contribution from organs other 
than the tumour was neglected. 
 
Statistical analysis 
In study I, the dependency of P-CgA on weight was analyzed by covariance analysis using log 
(P-CgA) as the dependent variable, group as factor, and tumour weight as covariate. The 
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logarithmic transform of P-CgA and P-CgA/tumour weight was used to stabilize variances. The 
interaction between group and tumour weight was included in the model. The differences 
between the groups regarding P-CgA/tumour weight was analyzed by one-way analysis of 
variance followed by multiple comparisons of groups 2 & 3 vs group 1 using Dunnett´s method. 
As the dependent variable, log (P-CgA/tumour weight) was used.  
In study II, the two-stage method (using the Statistical Analysis System (PROC MIXED)) was 
used for the uptake studies. The differences in tumour volume were analyzed by a two-tailed t 
test. For the correlation between tumour volume and P-CgA, Pearson´s correlation coefficient (R) 
was calculated. 
 
 
Clinical studies (III-V) 
Patients 
In study III, 107 consecutive patients with the midgut carcinoid syndrome and non-resectable 
liver metastases were treated with HAE at the Sahlgrenska University Hospital (1987-2006) and 
analyzed. The patients had hormonal symptoms and tU-5-HIAA levels were increased at least 
twofold, or showed radiological progression. Contraindications for HAE were tumour burden 
exceeding 50% of the liver volume, portal vein occlusion, and hyperbilirubinaemia. Relative 
contraindications were contrast allergy, coagulopathy, persistently raised liver enzymes, 
extrahepatic tumour dominance, and poor general performance status. 
In study IV, 26 patients with disseminated NE tumours (10 EPT, 10 midgut carcinoids, 3 rectal 
carcinoids, 1 pulmonary carcinoid, 1 duodenal gastrinoma, 1 NE pre-sacral tumour) treated with 
177Lu-octreotate at our hospital (2006-2008), were analyzed regarding radiological (RECIST) and 
biochemical (P-CgA) response absorbed dose to the kidney and glomerular filtration rate (GFR). 
These patients had all been subjected to previous multimodal treatment with combinations of 
surgery (primary and repeated), chemotherapy, somatostatin analogues, interferon-α, HAE, RF 
ablation, external radiation of the skeleton and in 4 patients OLT. 
In study V, 6 patients (three with carcinoids and three with EPT) previously treated by OLT for 
metastases confined to the liver, had developed recurrence. Four patients were treated with PRRT 
x 4 due to non-resectable recurrence, and 2 patients were treated in an adjuvant setting with 
PRRT x 2 after tumour excision. Routine haematology, liver and kidney function tests (GFR) and 
tumour markers were performed prior to each therapy and at follow-up. Radiological tumour 
responses of liver and lymph node metastases were evaluated according to RECIST-criteria.  
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Hepatic artery embolization procedure (III) 
HAE was performed by a transfemoral approach using a Tracker®-18 infusion catheter (Target 
Therapeutics, Los Angeles, California, USA) (Chuang, 1988; Coldwell, 1990). Angiography was 
used to confirm the patency of the portal vein. Branches of the hepatic artery were embolized 
selectively, usually in two sessions, including the right and the left hepatic artery, respectively. In 
patients with large tumour burden, smaller branches were embolized selectively. The 
embolization material in the early part of the series was gelatin powder and later in the series 
polyvinyl alcohol particles (45-150 µm). The patients were provided with epidural anaesthesia 
during the procedure, and monitored haemodynamically. Broad-spectrum antibiotics and 
somatostatin analogues were administered. Repeat HAE was considered when progressive 
disease was detected by two consecutive CT scans with an interval of at least 6 months, and tU-5-
HIAA concentration increased at least twofold relative to that recorded after the previous HAE; 
repeat HAE was performed in 19 out of 107 patients. 
 
Peptide receptor radionuclide therapy (IV-V) 
In study IV, each patient was scheduled for 4 treatment sessions, each with 8 GBq 177Lu-
octreotate, 6 weeks apart. The indications for treatment were progressive disease despite 
conventional therapy, and a tumour uptake of the radiopharmaceutical of at least twice the liver-
uptake on octreotide scintigraphy. Somatostatin analogue treatment was cessated before PRRT to 
enhance the tumour uptake. During radiotherapy, a lysine/arginin-solution was administered i.v. 
for kidney protection (Rolleman et al., 2003). The absorbed dose to each kidney was calculated 
with the conjugate view method after each session. The accumulated kidney dose limit used was 
set at 27 Gy. The radiological response was evaluated by measuring tumour size using RECIST-
criteria on CT-scans before and after treatment. Biochemical response was evaluated by 
comparing P-CgA before and after treatment. Haematological toxicity was evaluated according to 
the Common Toxicity Criteria (CTC) scale. Renal function was assessed by measuring GFR, 
either by Cr-EDTA-or iohexolclearance. 
In study V, two patients had their treatment at the Erasmus Medical Center, Rotterdam, The 
Netherlands. After 2005, all patients were treated at the Sahlgrenska University Hospital. The 
patients were treated up to a cumulative activity of 28-30 GBq, which corresponds to a bone 
marrow dose of 2 Gy. Patients with non-resectable recurrences received a cumulative renal dose 
less than 27.5 Gy (1-4 radiotherapies, 4-6 weeks apart). Two patients treated in an adjuvant 
setting only received PRRT x 2 each.  
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Somatostatin receptor scintigraphy 
When examined with somatostatin receptor scintigraphy, the patients received 10-20 µg of [111In 
DTPA-D-Phe1]-octreotide by i.v. injection. The administered activity was 190-300 MBq. A 
gamma camera (General Electric 400 AC/T) equipped with a medium-energy parallel-hole 
collimator connected to a GE STARCAM computer system was used. Static images were 
acquired for 10 min or until 500 kcounts were collected.  
 
Statistical analysis 
In study III, a stepwise Cox regression was used to build a statistical model to select variables 
that correlated with survival; factors included were sex, age, previous octreotide treatment, 
previous treatment with cytotoxic agents, previous IFN-α treatment, presence of metastases to 
regional lymph nodes, peritoneum or skeleton, increased liver transaminase levels in response to 
HAE (within 3 days) and changes of tU-5-HIAA and P-CgA levels at follow-up. Cox regression 
was used to study the relationship between survival and the percentage change of tU-5-HIAA and 
P-CgA levels, and also to determine the influence on survival of liver transaminase levels after 
HAE. Pearson´s correlation coefficients were calculated to study the covariation of biochemical 
responses following the first and repeat HAE procedures. In study IV, the change in tumour size 
according to RECIST-criteria and the change in GFR were analyzed using Wilcoxon matched 
pairs signed rank sum test. 
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RESULTS 
Tumour weight correlates with P-CgA in GOT 1-xenografted 
mice (I) 
P-CgA levels correlated with tumour weight in all animals (P<0.00001) (Fig. 2). 
Octreotide decreased the P-CgA/tumour weight ratio and a significant reduction 
was observed in the high-dose octreotide group (P<0.037). We found no difference 
in mean tumour weight between the groups, and no significant difference in mean 
increase of tumour volume between control animals and octreotide treated animals. 
All tumours were positive for CgA immunohistochemically.  
 
Fig 2. Correlation between P-CgA and tumour weight. There was a significant 
correlation between tumour weight and P-CgA levels in GOT 1-xenografted mice. 
Long-acting somatostatin decreased the P-CgA/tumour weight ratio, without 
influencing tumour weight. 
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177Lu-octreotate gives higher uptake, higher absorbed dose and 
better tumour reduction than 177Lu-octreotide in GOT 1-
xenografted mice (II) 
We found that the tumour uptake of 177Lu-octreotate was significantly higher than 
the tumour uptake of 177Lu-octreotide  (P=0.00061). The difference in activity 
concentration remained during the observation period of 13 days. The mean 
absorbed dose in tumour was 3-fold higher in animals given of 177Lu-octreotate 
than in animals given of 177Lu-octreotide. The reduction of tumour volume was also 
much more prominent in the animals given 177Lu-octreotate (P=0.003), with a 
reduction of tumour volume to 3% of its initial value after 37 days. There was a 
significant correlation between P-CgA levels and tumour volume (P<0.001). 
 
 
Fig 3. Uptake and effect of 177Lu-octreotate and 177Lu-octreotide in GOT 1-
xenografts. The tumour uptake of 177Lu-octreotate was significantly higher than 
the uptake of 177Lu-octreotide (left panel). The tumour volume reduction was much 
more pronounced in animals given 177Lu-octreotate (right panel), note the 
logarithmic scale. 
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Successful HAE correlates with prolonged survival in patients 
with midgut carcinoid (III) 
Twentysix out of 54 patients with complete data in their files showed >50% 
decrease of tU-5-HIAA and 19 out of 37 patients showed >50% decrease of P-
CgA. The mean decrease of tU-5-HIAA was 30.4 ± 8.0 (SEM) % and the mean 
decrease of P-CgA was 28.0 ± 10.4 (SEM) %; 71% of the patients experienced 
symptomatic relief, i.e. less diarrhea, reduction of flush or improved general well 
being (reflected by weight gain).  
Survival and complications. The median survival in the entire series (from the 
first HAE) was 56 months (range 1 – 204, 95% confidence interval (CI) 45 – 67) 
(Fig. 3).  
 
The multivariate stepwise Cox´ regression showed that male gender (Hazard Ratio 
(HR) 5.796), percentual decrease of tU-5-HIAA (HR 0.972), percentual decrease of 
P-CgA (HR 0.973) and post-embolization elevation of a liver transaminase (ASAT) 
(HR 1.104), were independent predictors of survival. There was a strong 
correlation by Cox´ regression between prolonged survival and reduction of tU-5-
HIAA (HR 0.991, P=0.003), or reduction of P-CgA (HR 0.987, P=0.001). Based 
Fig 3. Median survival after 
HAE. The median survival (from 
the first HAE) in the entire series 
of patients subject to HAE was 56 
months (range 1 –204, 95% CI 
45–67). 
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on the reduction of tU-5-HIAA by HAE, predicted survival was estimated. There 
was a 6 months gain in survival if the reduction of tU- 5-HIAA was ≥50% vs no 
reduction of tU-5-HIAA; another 6 months gain if the reduction was ≥75% (Fig.  
4).  
 
 
 
 
 
 
There was also a strong correlation between reduced survival and elevated liver 
transaminase (ASAT) levels after HAE (HR 1.031, P<0.001). 
Two patients died within one month after HAE; one due to hepatorenal syndrome 
and one due to rapidly progressive disease. The mortality rate was still low, 1.8 %; 
at centres of expertise it should be <5% (Ajani et al., 1994). There was one patient 
with HAE-related sepsis with uneventful outcome. The minor complications that 
 
Fig 4. Predicted survival based on decrease in tU-5-HIAA levels after   HAE. 
Compared to no reduction of tU-5-HIAA there was 6 months gain of survival if 
the tumour marker reduction was 50 %; another 6 months gain of survival if the 
reduction was 75 % 
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occurred were 4 patients with liver abscess, one with mild pancreatitis and two with 
total occlusion of the common hepatic artery; all had uneventful outcomes. 
Response to repeat HAE. For 6 out of 19 patients, who underwent repeat HAE on 
tumour progression, complete biochemical data were available to study changes of 
tU-5-HIAA in response to the first and repeat HAE. In these patients the 
biochemical response to repeat HAE correlated strongly with the biochemical 
response to the primary HAE (P=0.002) (Fig. 5).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PRRT results in objective tumour reduction and impaired 
kidney function; it can be optimized by monitoring absorbed 
dose to the kidney in patients with GEP-NETs (IV) 
Twenty-six patients with disseminated GEP-NETs treated with PRRT using 177Lu-
octreotate, were analyzed regarding absorbed dose to the kidneys, radiological and 
biochemical response, haematological toxicity and renal function. 
 
Fig. 5. Biochemical response to repeat HAE. The biochemical response (tU-
5-HIAA) to repeat HAE correlated significantly (P=0.002) with the 
biochemical response to the primary HAE. 
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Radiological response to PRRT. Sixteen out of 26 patients could be evaluated 
radiologically. Ten either lacked suitable lesions (not measurable on CT) (n = 3), 
died of disease before follow-up (n = 3) or are due to follow-up (n = 4). The 
radiological tumour response varied from a 54% increase of tumour size 
(progression) to a 79% decrease (regression). Six out of 16 (38%) showed partial 
response (PR) according to RECIST-criteria. Eight out of 16 (50%) showed stable 
disease (SD) and two out of 16 (13%) showed progressive disease (PD). No 
complete remission (CR) was observed (Fig. 6).  
 
 
 
Fig. 6. Radiological response to PRRT. A partial response (RECIST) was 
observed in 6 out of 16 patients with GEP-NETs treated with 177Lu-octreotate. 
 
The radiological response according to RECIST was not significant, when analyzed 
by Wilcoxon rank sum test. Figure 7 illustrates a favourable radiological response 
in a 52 years old patient with hepatic metastases of EPT, accompanied by reduced 
uptake on octreotide scintigraphy (Fig. 7). 
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Fig. 7. Radiological and scintigraphic evaluation of PRRT. Marked radiological 
tumour response (upper panel) two years after PRRT and reduced scintigraphic 
tumour uptake one year after treatment (lower panel) in a patient with liver 
metastases of EPT. Comparable investigations before (left) and after (right) 
treatment (right). Tumours indicated by arrows. 
 
Absorbed dose to the kidneys and glomerular filtration rate. The mean 
absorbed dose to the kidneys was 24 Gy ± 6 (SEM). Four PRRT were given 11 out 
of 26 patients. One patient had 5 PRRT, while 10 out of 26 had less than 4 PRRT, 
since they reached the kidney dose limit already after 2-3 treatments. Four patients 
did not reach the dose limit of the kidney; they thus have the possibility of 
additional PRRT. The mean GFR before treatment was 80 ml/1.73 m2/min ± 4 
(SEM). At follow-up the mean GFR was 70 ml/1.73 m2/min ± 4 (SEM). The 
decrease of GFR was significant (P=0.0013). 
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Biochemical response to PRRT. Seventeen out of 26 patients could be evaluated 
biochemically by measuring P-CgA. Nine patients either had normal P-CgA-levels 
before treatment (n = 4), died of disease before follow up (n = 3), or are due to 
follow-up (n = 2). Six out of 17 (35%) showed ≥30% decrease. Eight out of 17 
(47%) showed ≥20% increase. Three out of 17 (18%) showed neither ≥30% 
decrease nor ≥20% increase. 
 
PRRT in transplanted patients with non-resectable recurrence 
(V) 
Two patients (no 4 & 6) with recurrence of GEP-NETs after OLT were treated with 
PRRT as an adjunct to surgical resection. Patient no 4 with an isolated skeletal 
metastasis has no evidence of disease after metastasectomy followed by PRRT x 2. 
Patient no 6 recurred a second time with abdominal lymph node metastases, and 
has stable disease after lymph node excision followed by PRRT x 2. Both patients 
have been observed 2.5 years after PRRT. 
Four patients (no 1, 2, 3&5) with non-resectable recurrence of GEP-NETs after 
OLT, received PRRT for palliation. Patient no 1 was accepted for OLT despite 
tumour regions with high proliferation rate (hot spots with Ki67 >10%). She 
developed a s.c. metastasis in the neck, which was excised. After diagnosed 
continued dissemination she received PRRTx1, but died of rapid tumour 
progression. Patient no 2 developed lymph node and skeletal metastases and severe 
skeletal pain. After metastasectomy and external radiation he received PRRT x 4 
due to rapid tumour progression. There was an initial stabilization, but the patient 
died from progressive liver tumours 4.5 years after OLT. Patient no 3 developed 
multiple lymph node metastases and was treated with PRRT x 4, which stabilized 
the disease for 5 years. When graft metastases were detected rapid tumour 
progression followed; he died 10 years after OLT. Patient no 5 developed liver 
metastases and a pelvic recurrence. After resection of the pelvic tumour, PRRT x 4 
led to marked radiological response of the liver metastases. After 4 years he 
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recurred with bilobar liver metastases and abdominal para-aortic lymph node 
metastases. To avoid further renal toxicity, the liver metastases were treated with 
SIR, and subsequent excision of metastatic lymph nodes. He had an objective 
tumour response also to this treatment; he has now been observed 10 years after 
OLT (Fig. 8). 
 
 
 
 
Fig 8. Clinical outcome and time course of therapy in patients with GEP-NETs 
at tumour recurrence after OLT. Six patients were treated with PRRT for non-
resectable recurrence of NE tumours. A survival of 100-120 months was observed 
in 4 patients. 
 
Renal function. Glomerular filtration rate (GFR) was retrieved in 5 out of 6 
patients prior to OLT and varied between 67-129 ml/1.73 m2/min. There was a 
moderate reduction of GFR in 4 patients and a pronounced reduction in one patient 
biochemical response 
biochemical response 
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after OLT/immunosuppression. Five patients (no 2-6) could be evaluated before 
and after PRRT. Two patients with adjuvant treatment (no 4 & 6) each received 
PRRT x 2 with no impairment of GFR. Three patients with palliative treatment 
(PRRT x 4) showed a reduction of GFR by 29% (pat no 3) and 15% (pat no 5), and 
stable function in one (pat no 2) (Fig. 9). 
 
 
 
 
Fig. 9. Influence of immunosuppression and subsequent PRRT on renal 
function in patients with metatstaic GEP-NETs, subjected to OLT. GFR 
remained stable after PRRT in 5 evaluable patients with recurrence of GEP-NETs 
after OLT; pat no 4 & 6 received PRRT x 2, pat no 2, 3 & 5 received PRRT x 4. 
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DISCUSSION 
 
Biochemical markers of tumour burden 
To evaluate the therapeutic effect of different treatments, reliable and readily 
available markers of tumour burden are needed. P-CgA is used both for diagnostic 
purposes and to follow the clinical course of NE tumour disease. P-CgA has been 
claimed to be the most sensitive marker for GEP-NETs (Bajetta et al., 1999; 
Baudin et al., 1998; Nobels et al., 1998). Sampling of P-CgA is a simple test 
compared to urinary collections for 5-HIAA analyses. It can be used both for 
functioning and non-functioning tumours. Earlier studies have shown a correlation 
between tumour size and P-CgA levels in hereditary (small) pheocromocytoma 
(Hsiao et al., 1990b) and in nude mice bearing human neuroblastoma (Wassberg et 
al., 1996). These correlations cannot directly be translated to the clinical situation 
of NE tumours with spread to several organs. Assessing total tumour volume from 
a secretory product released into the circulation called for another approach, and 
our nude mice model with xenografted human carcinoid (GOT 1) offered a 
possibility to study the relationship between P-CgA and carcinoid tumour volume. 
One must bear in mind that P-CgA levels may be influenced by several host 
factors. Impaired renal function prevents the excretion of peptides and elevates P-
CgA (Hsiao et al., 1990a). Atrophic gastritis, or proton pump inhibition, causes 
hypergastrinemia and ECL-cell hyperplasia associated with elevated P-CgA (Borch 
et al., 1997; Sanduleanu et al., 1999). Serotonin release in response to hyperemesis 
in patients after treatment with cytotoxic agents, may also increase P-CgA 
(Cubeddu et al., 1995). We found that tumour weight strongly correlated with P-
CgA levels in GOT 1-xenografted mice (I). Octreotide treatment decreased P-CgA 
in a dose-dependent manner, but tumour size was not reduced in response to such 
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treatment. In study II we found a strong correlation between tumour size and P-
CgA after PRRT. Together these findings indicate that P-CgA is a reliable marker 
of carcinoid tumour burden and is suitable for monitoring therapeutic effects in our 
experimental model. The biochemical response to PRRT in patients with GEP-
NETs, was estimated by P-CgA levels (IV). Since renal function was at the same 
time impaired, it is reasonable to assume that the relation between tumour volume 
and P-CgA values was not linear for these patients. 
 
Treatment of disseminated neuroendocrine tumours  
Peptide receptor radionuclide therapy  
PRRT is a new modality to treat disseminated GEP-NETs, taking advantage of the 
high SSTR-expression in these tumours. We compared the tumour uptake and 
tumour response in our xenograft model of the human midgut carcinoid GOT 1, 
when treated with either 177Lu-octreotide or 177Lu-octreotate (II). Treatment with 
177Lu-octreotate resulted in 2-fold higher tumour uptake. The activity concentration 
level remained significantly higher for a prolonged period, which contributed to a 
3-fold higher absorbed dose vs treatment with 177Lu-octreotide. These results 
provided in vivo data of the uptake and also enabled detailed estimation of absorbed 
doses.  
PRRT to patients with GEP-NETs was initiated at the Sahlgrenska University 
Hospital 2006. The radiological (RECIST) and biochemical (P-CgA) evaluation of 
the first 26 treated patients (IV) revealed a 38% partial response rate radiologically, 
in line with previous reports (Kwekkeboom et al., 2008; Kwekkeboom et al., 2005). 
There was no evident correlation between the radiological and biochemical 
responses, which might partly be explained by the relatively short follow-up. 
Furthermore, P-CgA levels are influenced by renal function (Hsiao et al., 1990a), 
which can be impaired by PRRT. Other centres have reported mild renal effects of 
PRRT, but we found a 12% reduction of GFR (P =0.0013). This must be 
considered when changes in P-CgA levels by PRRT are evaluated. It also 
   42 
emphasizes that the kidney is a dose-limiting organ. Individualization of PRRT can 
be achieved, if the accumulated absorbed kidney dose is monitored. In our series 
(IV), four out of 26 patients were identified as candidates for additional PRRT 
without exceeding the kidney dose limit (27 Gy). More precise methods for 
calculating the kidney dose, e.g. using SPECT images for quantification of the 
activity concentration together with better knowledge of the kidney dose limit, will 
contribute to an optimized individual dose planning aiming at delivering a high 
dose to the tumour without serious impairment of kidney function.  
 
Hepatic artery embolization 
HAE is an established palliative treatment for liver metastases of GEP-NETs 
resulting in good control of hormonal symptoms (Chamberlain et al., 2000; Coupe 
et al., 1989; Geterud et al., 1990; Gupta et al., 2003; Schell et al., 2002; Wängberg 
et al., 1996). It appears to be especially favourable for patients with midgut 
carcinoid tumours (Eriksson et al., 1998). A survival advantage has been suggested 
in previous small series (Jacobsen et al., 1995; Mitty et al., 1985). In our series of 
107 consecutive patients with midgut carcinoid (III), we found a correlation 
between tumour marker reduction (tU-5-HIAA and P-CgA) and prolonged 
survival. It was possible to estimate the gain in survival; the relative reduction in 
tumour markers corresponded to a graded survival advantage. Also immediate 
biochemical changes, i.e. the increase of liver transaminase levels, correlated with 
reduced survival. This finding supports a more selective HAE-procedure, i.e. 
limited embolization of more peripheral branches to avoid damage to normal liver 
parenchyma. Induction of tumour ischemia is most likely not the only mechanism 
of action of HAE. Natural killer cells with increased tumouricidal activity rapidly 
accumulates in central venous blood of patients with radiological responses to 
HAE. Bilobar tumour regression was shown in individual patients after unilateral 
HAE, suggesting involvement of systemic mechanisms. It was suggested that 5-HT 
released from tumour cells by ischemia decreased the monocyte inhibition of 
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natural killer cells (Wängberg et al., 1995). Criteria to identify responsive patients 
will lead to more precise indications for HAE. Our finding that the response to the 
first HAE correlated with the response to repeat HAE, indicates that it will be 
possible to identify responsive patients in advance. A randomized, prospective 
study of HAE in patients with hepatic metastases of carcinoids has not been 
performed, since no effective pharmacological treatment arm has been available.  
 
PRRT in patients liver transplanted for GEP-NETs 
In patients, who have been treated with OLT due to metastatic GEP-NETs limited 
to the liver, recurrence is early detected due to a strict follow-up protocol. Surgical 
treatment is preferred if the recurrent lesion is resectable, but in case of 
multilocular recurrences systemic therapy is required, especially since there is no 
effective chemotherapy for many of these tumours (Rougier & Mitry, 2000); 
chemotherapy can also be hazardous for immunosuppressed patients. PRRT 
therefore offers an attractive therapeutic alternative for transplanted patients, even 
though they have reduced GFR (Herlénius et al., 2008) and PRRT can cause 
radiation-related nephrotoxicity (IV). In our pilot series of 6 OLT patients, with 
monitored absorbed doses to the kidney, we found a moderate reduction of GFR by 
PRRT only in two patients, suggesting that PRRT can be safely used also under 
these conditions. Multilocular recurrences in OLT patients may be well suited for 
PRRT, since recurrent disease is early detected, i.e. the total tumour volume is 
relatively small, which is favourable for the therapeutic outcome (Valkema et al., 
2002). In our study, two patients with minimal residual disease received PRRT x 2 
in an adjuvant setting: One has no sign of recurrence and the other has SD after 2.5 
years. These results support that PRRT can be a valuable treatment option to 
prevent, or delay, tumour recurrence in OLT patients. 
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Optimization of current treatment alternatives 
The palliative treatment for disseminated GEP-NETs needs to be further optimized, 
e.g. methods for early identification of responders to HAE and superselective 
embolization procedures are required. PRRT via highly expressed SSTR has a 
proven effect in clinical studies. To date most treated patients had advanced 
tumours and were beyond curative therapy. Experimental studies indicate that the 
treatment protocols can be optimized, e.g. low amounts of 177Lu-octreotate prior to 
PRRT can upregulate SSTR2 in the tumour tissue leading to increased uptake of 
radionuclide and enhanced therapeutic effects (Bernhardt et al., 2007; Oddstig et 
al., 2006). Another promising option is the radiosensitizing action of the pyridyl 
cyanoguanidine CHS 828, which is a poly(ADP-ribose)polymerase 1 (PARP1) 
inhibitor (Olesen et al., 2008; Watson et al., 2009). Nicotine amide adenine 
dinucleotide (NAD+) is essential for enzymatic redox reactions, including 
adenosine triphosphate (ATP) production, but is also a substrate for poly (ADP) 
ribosylation (catalyzed by PARP1), which is activated by DNA strand breaks, e.g. 
induced by radiotherapy. If the re-synthesis of NAD+ is inhibited by PARP1 
inhibition, the energy metabolism of the irradiated tumour is severely impaired and 
radiation-induced tumour cell damage is enhanced (Watson et al., 2009). 
Interference with the apoptotic pathway and death receptors can probably also 
potentiate the radiotherapeutic effects (Schulze-Bergkamen et al., 2009). 
Our series of patients (IV) was characterized by multimodal therapy prior to PRRT. 
The patients all had advanced disease with large tumour burden and our results 
were similar to the Rotterdam series (Kwekkeboom et al., 2008). One way to better 
select patients for PRRT is to analyze the profile of expressed SSTR subtypes in 
tumour biopsies (Kubota et al., 1994; Kölby et al., 1998), so that a suitable 
radiopharmaceutical with a high affinity for the particular subtypes expressed, or a 
pan-analogue (SOM 230), can be selected in order to obtain an optimal tumour-
specific uptake. Radionuclides with different ranges can be chosen in relation to 
tumour size (Bernhardt et al., 2001). Combinations of several radionuclides can 
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also be used when the size of different lesions vary (de Jong et al., 2005). Finally 
monitoring of the total absorbed dose to the kidneys is a valuable tool to optimize 
the dose to each patient. The use of PRRT in an adjuvant setting to eradicate 
minimal residual disease, or as a precaution in patients with high-risk tumours after 
intentionally curative surgery, has not yet been established. The two pilot cases in 
study V may indicate curative treatment, or long periods of stable disease, when 
minimal tumour volumes are treated. 
 
Future aspects 
The increasing knowledge of cancer cell biology has revealed a number of 
signalling pathways in cancer cells that may be selectively targeted for anti-cancer 
therapy. Our knowledge of cellular signalling in GEP-NETs is limited. However, 
interference with some of the signalling pathways has been attempted in 
experimental studies as well as in phase 1 & 2 studies. 
Targeting growth factors (e.g. epidermal growth factor or platelet derived growth 
factor) and their receptors [using tyrosine kinase inhibitors (TKI) (Hobday et al., 
2006; Hobday et al., 2007) or monoclonal antibodies (ongoing study NIH:NCT 
00397384)], angiogenic factors (e.g. vascular endothelial growth factor) [using 
TKI (Raymond et al., 2009), monoclonals (Yao et al., 2008), endostatin (Kulke et 
al., 2006a), thalidomide (Kulke et al., 2006b)] and hormone receptors (SSTR and 
insulin-like growth factor 1 receptor) [using inhibitory analogues (Rinke et al., 
2009; Schally, 2008) or small molecules] expressed on NE tumours has been 
attempted and may provide new therapeutic options. Monotherapy with the 
multitarget TKI sunitinib significantly increased the progression-free survival of 
patients with advanced EPT in a recent randomized study (Raymond et al., 2009). 
In carcinoids interference with some signalling pathways (mTOR, PI3K, RAS/RAF 
and Notch) seems effective in experimental models (Greenblatt et al., 2007; Pitt et 
al., 2009; Van Gompel et al., 2005; Zitzmann et al., 2007) besides more general 
mechanisms as inhibition of the proteasome or histone deacetylation (Bolden et al., 
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2006; Karin et al., 2004; Shah et al., 2004). Several new agents to treat the rare NE 
tumour diseases will evidently appear in the near future. To gain rapid information 
about their usefulness randomized multicentre studies are required. 
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CONCLUSIONS 
 
1. Chromogranin A levels in plasma were closely related with tumour 
volume and were significantly reduced by a somatostatin analogue, i.e  
P-CgA is well suited for monitoring of the tumour volume in our 
xenograft model, but is influenced by somatostatin analogue treatment. 
2. 177Lu-octreotate is a more suitable radiopharmaceutical than 177Lu-
octreotide for treatment of SSTR-expressing NE tumours. P-CgA was 
an accurate marker of volume and response to treatment in an 
experimental setting. 
3. Hepatic artery embolization was a safe and well tolerated treatment 
modality. It provided good hormonal control in patients with the midgut 
carcinoid syndrome and prolonged survival of biochemically responsive 
patients. Furthermore, repeat HAE can be considered in patients with 
favourable response to the first procedure. 
4. Peptide receptor radionuclide therapy can be optimized by using the 
accumulated dose to the kidneys as a limiting factor, so that the highest 
dose possible can be used without causing nephrotoxicity. 
5. Peptide receptor radionuclide therapy provided a safe treatment option 
for patients with non-resectable recurrence of SSTR-expressing NE 
tumours, previously treated with liver transplantation; in individual 
patients objective tumour regression, or disease-stabilization, was seen. 
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